Sunshine Biopharma, Inc. (SBFM) stock forecast & analysis
0.7000
NasdaqCM · USD
Up: +0.3021, +75.9%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.4095
- Previous close
- 0.3979
- Day range
- 0.4000 – 1.54
- 52-week range
- 0.3560 – 24.30
- Volume (shares)
- 171.33M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 4.31M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.35
- Market cap
- 3.02M
Market Scanner’s AI analysis of Sunshine Biopharma, Inc. (SBFM), updated October 2026: Sunshine Biopharma's public offering and generic drug launch contrasted with significant stock price declines and bearish technical indicators.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Sunshine Biopharma, Inc. (SBFM) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Sunshine Biopharma's public offering and generic drug launch contrasted with significant stock price declines and bearish technical indicators.
Recent analyses for Sunshine Biopharma (SBFM) covered a $6.0 million public offering and the launch of a generic version of Zofran in Canada. Progress in its coronavirus drug candidate's IND-enabling studies was also noted. However, the stock has experienced significant price declines over the past 7 and 30 days, trading well below its 50-day and 200-day simple moving averages, with short-term downward momentum indicated by technical indicators.
SBFM news & sentiment
News reports highlighted a public offering and a drug launch, alongside an analyst upgrade. Social media discussions focused on the stock's significant price declines and bearish technical indicators, with notable trading activity observed.
SBFM technical picture
The stock price has seen significant declines over the past week and month, trading substantially below its 50-day and 200-day moving averages. Short-term momentum indicators suggest a downward trend, though a high Money Flow Index reading may indicate strong buying pressure. The Relative Strength Index is trending towards oversold territory.
Fundamentals
Sunshine Biopharma reported a slight year-over-year quarterly revenue decline and negative profit and operating margins. The company also showed a negative return on equity, indicating profitability challenges.
Factors discussed — upside
- Public offering priced at $6.0 million.
- Analyst upgrade to 'Buy'.
- Launched generic version of Zofran in Canada.
- Lead coronavirus drug candidate advanced into IND-enabling studies.
- Mentioned in 'Most Active Stocks' list, suggesting heightened trading interest.
Factors discussed — risks
- Stock price declined 9.4% in the last 7 days.
- Stock price declined 38.6% over the past 30 days.
- Trading below 50-day SMA by 33.1%.
- Trading below 200-day SMA by 89.3%.
- 10-day EMA below last close, indicating short-term downward momentum.
- Public offerings
- Drug development pipeline
- Technical indicators
- Stock performance
Summary updated .
SBFM technical indicators
Common technical indicators for SBFM, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.05 | Price below |
| 10-day exponential moving average | 0.67 | Price above |
| Relative strength index (14-day) | 40.60 | Neutral |
| MACD line (12/26/9) | -0.1616 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 0.46 – 1.20 | Price inside the bands |
Analyses
Recent SBFM.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-08 SBFM.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Sunshine Biopharma, Inc.?
- The bull case for Sunshine Biopharma (SBFM) centers on its recent public offering and the expansion of its product offerings, including the launch of a generic version of Zofran in Canada and progress on its lead coronavirus drug candidate. The company also received an analyst upgrade and was noted for heightened trading interest.
- What are the risks for Sunshine Biopharma, Inc.?
- Risks for Sunshine Biopharma (SBFM) include significant recent stock price declines, with the price trading well below its 50-day and 200-day simple moving averages. Technical indicators suggest short-term downward momentum and a trend towards oversold territory.
- Is Sunshine Biopharma, Inc. bullish or bearish?
- Recent AI analyses of Sunshine Biopharma, Inc. examined factors on both sides. Discussed upside: The bull case for Sunshine Biopharma (SBFM) centers on its recent public offering and the expansion of its product offerings, including the launch of a generic version of Zofran in Canada and progress on its lead coronavirus drug candidate. The company also received an analyst upgrade and was noted for heightened trading interest. Discussed risks: Risks for Sunshine Biopharma (SBFM) include significant recent stock price declines, with the price trading well below its 50-day and 200-day simple moving averages. Technical indicators suggest short-term downward momentum and a trend towards oversold territory. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Sunshine Biopharma, Inc.?
- News reports highlighted a public offering and a drug launch, alongside an analyst upgrade. Social media discussions focused on the stock's significant price declines and bearish technical indicators, with notable trading activity observed.
- How does Market Scanner analyse Sunshine Biopharma, Inc.?
- Every analysis of Sunshine Biopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Sunshine Biopharma, Inc.?
The bull case for Sunshine Biopharma (SBFM) centers on its recent public offering and the expansion of its product offerings, including the launch of a generic version of Zofran in Canada and progress on its lead coronavirus drug candidate. The company also received an analyst upgrade and was noted for heightened trading interest.
What are the risks for Sunshine Biopharma, Inc.?
Risks for Sunshine Biopharma (SBFM) include significant recent stock price declines, with the price trading well below its 50-day and 200-day simple moving averages. Technical indicators suggest short-term downward momentum and a trend towards oversold territory.
Is Sunshine Biopharma, Inc. bullish or bearish?
Recent AI analyses of Sunshine Biopharma, Inc. examined factors on both sides. Discussed upside: The bull case for Sunshine Biopharma (SBFM) centers on its recent public offering and the expansion of its product offerings, including the launch of a generic version of Zofran in Canada and progress on its lead coronavirus drug candidate. The company also received an analyst upgrade and was noted for heightened trading interest. Discussed risks: Risks for Sunshine Biopharma (SBFM) include significant recent stock price declines, with the price trading well below its 50-day and 200-day simple moving averages. Technical indicators suggest short-term downward momentum and a trend towards oversold territory. These are descriptive observations, not a recommendation.
What is the latest sentiment on Sunshine Biopharma, Inc.?
News reports highlighted a public offering and a drug launch, alongside an analyst upgrade. Social media discussions focused on the stock's significant price declines and bearish technical indicators, with notable trading activity observed.
How does Market Scanner analyse Sunshine Biopharma, Inc.?
Every analysis of Sunshine Biopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh SBFM.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.